Clinicopathological and cellular senescence biomarkers in chronic stalled wounds

Int J Dermatol. 2024 Sep;63(9):1227-1235. doi: 10.1111/ijd.17072. Epub 2024 Feb 13.

Abstract

Background: Chronic wounds have been associated with an elevated burden of cellular senescence, a state of essentially irreversible cell cycle arrest, resistance to apoptosis, and a secretory phenotype. However, whether senescent cells contribute to wound chronicity in humans remains unclear. The objective of this article is to assess the role of clinicopathological characteristics and cellular senescence in the time-to-healing of chronic wounds.

Methods: A cohort of 79 patients with chronic wounds was evaluated in a single-center academic practice from February 1, 2005, to February 28, 2015, and followed for up to 36 months. Clinical characteristics and wound biopsies were obtained at baseline, and time-to-healing was assessed. Wound biopsies were analyzed histologically for pathological characteristics and molecularly for markers of cellular senescence. In addition, biopsy slides were stained for p16INK4a expression.

Results: No clinical or pathological characteristics were found to have significant associations with time-to-healing. A Cox proportional hazard ratio model revealed increased CDKN1A (p21CIP1/WAF1) expression to predict longer time-to-healing, and a model adjusted for gender and epidermal hyperplasia revealed increased CDKN1A expression and decreased PAPPA expression to predict longer time-to-healing. Increased p16INK4a staining was observed in diabetic wounds compared to non-diabetic wounds, and the same association was observed in the context of high dermal fibrosis.

Conclusions: The findings of this pilot study suggest that senescent cells contribute to wound chronicity in humans, especially in diabetic wounds.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers* / analysis
  • Biomarkers* / metabolism
  • Biopsy
  • Cellular Senescence*
  • Chronic Disease
  • Cyclin-Dependent Kinase Inhibitor p16* / analysis
  • Cyclin-Dependent Kinase Inhibitor p16* / metabolism
  • Cyclin-Dependent Kinase Inhibitor p21* / analysis
  • Cyclin-Dependent Kinase Inhibitor p21* / metabolism
  • Female
  • Fibrosis
  • Humans
  • Male
  • Middle Aged
  • Skin / metabolism
  • Skin / pathology
  • Time Factors
  • Wound Healing*

Substances

  • Cyclin-Dependent Kinase Inhibitor p16
  • Cyclin-Dependent Kinase Inhibitor p21
  • Biomarkers
  • CDKN1A protein, human
  • CDKN2A protein, human